Key Highlights

● Abivax plans to submit its obefazimod NDA in ulcerative colitis by the end of 2026.

● The first-half net loss widened to €165.9 million from €100.8 million.

● July's offering raised about US$920 million gross, with cash runway guided into Q4 2029.

● Crohn's disease Phase 2b ENHANCE-CD topline results are expected in mid-2027.

Abivax SA (NASDAQ:ABVX) is a French clinical-stage biotechnology company whose American Depositary Shares trade on the Nasdaq under the symbol ABVX, while its ordinary shares are also listed on Euronext Paris. Its half-year report for the six months ended 30 June 2026, published on 21 September 2026 and furnished to the US Securities and Exchange Commission on Form 6-K, is the company's most recent full financial update. The report centres on obefazimod, an investigational treatment for ulcerative colitis, and on how the company intends to fund it through regulatory review.

Historical results for the first half of 2026

Figures in the release are stated in euros. The net loss for the first half of 2026 was €165.9 million, compared with €100.8 million a year earlier. The operating loss widened to €140.3 million from €93.7 million. Research and development spending was €107.9 million, which the company described as 75.5 per cent of operating expenses, while general and administrative costs rose to €30.4 million from €16.3 million and sales and marketing costs reached €4.6 million from €1.5 million. Operating cash outflow was €102.5 million, up from €66.6 million. These are reported, historical numbers.

A one-off item also affected the period. Abivax completed a repurchase of royalty certificates on 7 May 2026 for total consideration of US$90 million, split between US$45 million in cash and US$45 million in equity, comprising 403,347 ordinary shares. The company said this produced an expense of roughly €43.2 million in the second quarter.

Balance sheet and runway

At 30 June 2026 cash, cash equivalents and short-term investments totalled €402.4 million. The picture changed after the period end: in July 2026 the company completed an underwritten offering of 7,360,000 ADSs, with gross proceeds of about US$920 million and net proceeds of about US$874.1 million, which the release translated at roughly €767.1 million. Based on current operating assumptions, management says its cash runway extends into the fourth quarter of 2029. That statement is management guidance, not a certainty, and it depends on the pace of spending and the outcome of regulatory events. The company did not provide revenue or earnings guidance.

Clinical and regulatory progress

The release lists several milestones during 2026. Three-year data from the Phase 2a/2b open-label extension known as Study 108 were reported on 22 May. Results from the Phase 3 ABTECT Maintenance trial in moderately to severely active ulcerative colitis followed on 1 June, and on 29 June the company reported positive results from Part 2 of that trial in refractory patients. On 30 July it described a positive pre-NDA interaction with the US Food and Drug Administration for obefazimod.

Disclosed next steps

Abivax says it plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026, and it expects topline results from the Phase 2b ENHANCE-CD induction trial in Crohn's disease in mid-2027. On the leadership side, Chris Rabbat succeeds Fabio Cataldi as Chief Medical Officer, with Dr Cataldi leaving in the fourth quarter of 2026, and Tim Kelly has been appointed Chief Technical Officer.

A Heavily Funded Position Ahead of a Year-End Filing

For those following the sector, the significance is that a company with no approved product has moved to a heavily funded position ahead of a planned regulatory filing. The July offering substantially reduces near-term financing risk, although it does not remove clinical, regulatory or commercial risk. A filing is not an approval, and the agency's review timetable, any requests for additional data, and the eventual label are all unknown. Crohn's disease results are also more than eight months away on the company's own schedule.